Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients

被引:160
作者
Kyrgidis, Athanassios
Vahtsevanos, Konstantinos
Koloutsos, Georgios
Andreadis, Charalampos
Boukovinas, Ioannis
Teleioudis, Zisis
Patrikidou, Anna
Triaridis, Stefanos
机构
[1] Aristotle Univ Thessaloniki, Dept Oral & Maxillofacial Surg, Dept Clin Oncol 3, GR-54006 Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Dept Clin Oncol 2, Theagenio Canc Hosp, GR-54006 Thessaloniki, Greece
[3] Aristotle Univ Thessaloniki, Univ Dept Otolaryngol 1, AHEPA Hosp, GR-54006 Thessaloniki, Greece
关键词
D O I
10.1200/JCO.2008.16.2768
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Osteonecrosis of the jaws (ONJ) was initially described in 2001 in patients receiving intravenous bisphosphonate (BP) treatment. The objective of the present study was to determine whether routine dental procedures can be considered as possible risk factors for the development of ONJ in breast cancer patients receiving BP. Patients and Methods Twenty breast cancer patients who developed ONJ receiving BP treatment were included in group A, whereas group B consisted of 40 matched controls (breast cancer patients who did not progress to ONJ receiving BP treatment). Routine dental care, smoking habits, history of tooth extraction, use of dentures, and root canal therapy were recorded. Results Our results indicate that history of tooth extraction during zoledronic acid treatment (adjusted odds ratio [OR] = 16.4; 95% CI, 3.4 to 79.6) and the use of dentures (adjusted OR = 4.9; 95% CI, 1.2 to 20.1) increase the risk of developing ONJ. Conclusion The outcome of the present study suggests early referral by oncologists for dental evaluation for every patient to be treated with BP. These results raise the current American Society of Clinical Oncology Level of Evidence linking certain dental procedures with ONJ from V to III. Further studies are needed to assess other possible risk factors and also to highlight the etiopathogenesis mechanism of ONJ.
引用
收藏
页码:4634 / 4638
页数:5
相关论文
共 16 条
  • [1] [Anonymous], ASCO NCCN QUAL MEAS
  • [2] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
    Bamias, A
    Kastritis, E
    Bamia, C
    Moulopoulos, LA
    Melakopoulos, L
    Bozas, G
    Koutsoukou, V
    Gika, D
    Anagnostopoulos, A
    Papadimitriou, C
    Terpos, E
    Dimopoulos, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8580 - 8587
  • [3] Tobacco smoking and breast cancer
    Baptista, Mauricio Z.
    Altundag, Kadri
    Akyurek, Serap
    [J]. BREAST JOURNAL, 2006, 12 (04) : 396 - 397
  • [4] The role of bone markers in metastatic bone disease
    Coleman, RE
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 : 1 - 2
  • [5] Metastatic bone disease: clinical features, pathophysiology and treatment strategies
    Coleman, RE
    [J]. CANCER TREATMENT REVIEWS, 2001, 27 (03) : 165 - 176
  • [6] Clinical features of metastatic bone disease and risk of skeletal morbidity
    Coleman, Robert E.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6243S - 6249S
  • [7] THE RISK OF DETERMINING RISK WITH MULTIVARIABLE MODELS
    CONCATO, J
    FEINSTEIN, AR
    HOLFORD, TR
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) : 201 - 210
  • [8] Dimopoulos MA, 2006, HAEMATOL-HEMATOL J, V91, P968
  • [9] Durie BGM, 2005, NEW ENGL J MED, V353, P99
  • [10] García-Closas M, 1999, AM J EPIDEMIOL, V149, P689